Rybelsus vs semaglutide: same molecule, very different licences

What the MHRA approval record actually shows

The confusion is understandable: Rybelsus, Ozempic and Wegovy all contain semaglutide, manufactured by Novo Nordisk. The molecule is the same. What differs is the licensed indication, the dose range, and the clinical evidence each authorisation rests on.

Rybelsus tablets come in 3 mg, 7 mg and 14 mg strengths. They were licensed by the MHRA for adults with type 2 diabetes, not for obesity, not for weight management alongside lifestyle changes. If you are weighing up how oral semaglutide compares with traditional diabetes medicines, that context matters before drawing any conclusions about switching or combining treatments. The NHS medicines page for semaglutide sets this out plainly.

Wegovy tablets occupy a separate regulatory slot. The MHRA approved them on 11 June 2026 specifically for weight management in adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition. The dose ladder runs from 1.5 mg through 4 mg and 9 mg to a 25 mg maintenance dose, titrated by a prescriber over several months. That schedule is clinically and numerically distinct from the Rybelsus diabetes range. The full breakdown of how oral semaglutide differs from injectable Ozempic covers the mechanistic similarities in more depth.

The short version: same active ingredient, two separate licensed products, two different clinical populations, two non-overlapping dose ranges.

Trial data that sit behind each licence

The evidence base for Rybelsus in diabetes is robust but it was not designed to answer a weight-loss question. The PIONEER programme (the phase 3 trials supporting the Rybelsus diabetes licence) tested glycaemic control as the primary endpoint. Weight changes were measured but as a secondary variable, and the doses studied (up to 14 mg) are substantially below the 25 mg maintenance dose of the Wegovy weight-loss tablet.

Wegovy tablets rest on a different evidence base. The OASIS 4 trial (a phase 3 study of 307 adults with obesity or overweight and at least one weight-related condition, without diabetes, followed for 64 weeks) found an average body-weight reduction of around 13.6% versus approximately 2.4% on placebo, taken alongside lifestyle changes. Among participants who adhered fully to treatment, average weight loss reached roughly 17%. That is the figure the MHRA reviewed when granting the weight-loss licence.

On a like-for-like basis, the injectable Wegovy 2.4 mg pen produced around 15% average weight reduction in the STEP 1 trial, published in the New England Journal of Medicine. The tablet's results are somewhat lower, partly reflecting oral bioavailability constraints. Some patients prefer the tablet format precisely because there is no injection involved; others prioritise the higher average loss associated with injectable or dual-agonist options.

These are decisions made with a prescriber who knows your full picture, not comparisons to resolve from a search result alone.

A comparison of both oral semaglutide products

Worth noting on administration: both products require the same morning ritual, first thing on an empty stomach, a small amount of plain water, and a wait of at least 30 minutes before any food, coffee or other oral medicines. That window is clinically important for absorption and is the same reason the two products cannot simply be swapped without a prescriber's involvement.

What IS licensed for weight loss in the UK, and how to access it

Two medicines are currently licensed by the MHRA for weight management in the UK and dispensed by our pharmacy: Wegovy (semaglutide, both the injectable pen and the tablet approved in June 2026) and Mounjaro (tirzepatide), a dual GIP and GLP-1 receptor agonist made by Eli Lilly. Both are prescription-only medicines, no prescriber can issue either without a clinical assessment. Our weight-loss treatment overview sets out how they compare in plain terms.

For Mounjaro, NICE published its recommendation in December 2024 (NICE TA1026), covering adults with a BMI of 35 or above alongside at least one weight-related comorbidity for NHS access; private eligibility follows the licensed criteria, which start at BMI 30 or 27 with a qualifying condition. Wegovy tablets carry their own eligibility thresholds from the MHRA authorisation. Lower BMI thresholds apply for certain ethnic backgrounds under UK guidance.

If you have been taking Rybelsus for diabetes and your prescriber thinks semaglutide at higher doses may also help with weight, the transition pathway is a prescriber conversation, not a self-switch. The clinical considerations around switching from Rybelsus to Wegovy are covered in detail on that page.

Payday tends to prompt a spike in consultations mid-to-late month, so if your timing works out that way, our same-day dispatch before 12pm means you can have a decision from a real prescriber and a next-working-day delivery without rearranging much. Our clinical team reviews every application personally. If you want to understand costs before committing, the Wegovy tablet pricing page covers what the prescription includes. For anything else, our team is reachable via the contact page, and broader questions are answered in our FAQs.

Which option suits you (injectable or tablet, semaglutide or tirzepatide) is a clinical decision our prescribers work through with you individually. Start your free consultation and that conversation begins the same day.